| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development (including related party amounts of 228, 224, 686 and 670, respectively) | 14,589 | 15,738 | ||
| General and administrative (including related party amounts of 130, 134, 395 and 405, respectively) | 4,722 | 5,831 | ||
| Total operating expenses | 19,311 | 21,569 | ||
| Loss from operations | -19,311 | -21,569 | ||
| Interest income | 2,314 | 2,486 | ||
| Net loss | -16,997 | -19,083 | ||
| Net loss per share, basic | -0.3 | -0.34 | ||
| Net loss per share, diluted | -0.3 | -0.34 | ||
| Weighted-average shares of common stock outstanding, basic | 56,950,999 | 56,859,388 | ||
| Weighted-average shares of common stock outstanding, diluted | 56,950,999 | 56,859,388 | ||
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)